| 產(chǎn)品名稱 | VX 770 - Ivacaftor | Kalydeco |
| 產(chǎn)品貨號(hào) | Axon 2503 CAS [873054-44-5] MF C24H28N2O3MW 392.49 Purity: 99% Soluble in DMSO Description Orally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels. KEYWORDS: VX 770 | supplier | CFTR potentiator | Ivacaftor | Kalydeco | VX770 | [873054-44-5] | [1174930-71-2] | Ion Channel | Cystic Fibrosis | CF | FDA-approved | ATP-independent |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
VX 770 - Ivacaftor | KalydecoAxon 2503 CAS [873054-44-5] MF C24H28N2O3
DescriptionOrally bioavailable CFTR potentiator; FDA-approved drug for clinical application to patients with cystic fibrosis (CF). VX770 enhances spontaneous, ATP-independent activity of WT-CFTR to a similar magnitude as its effects on G551D channels. KEYWORDS: VX 770 | supplier | CFTR potentiator | Ivacaftor | Kalydeco | VX770 | [873054-44-5] | [1174930-71-2] | Ion Channel | Cystic Fibrosis | CF | FDA-approved | ATP-independent
Orally bioavailable CFTR potentiator
Chemical nameN-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide Parent CAS No.[873054-44-5] |
| 產(chǎn)品資料 |
